We developed our ADC technology to enable the creation of better therapies for people with cancer. Today ImmunoGen is a recognized leader in the field.
The concept of an ADC is simple: employ an antibody that binds to a target (its antigen) found on tumor cells to deliver a cancer-killing agent specifically to these cells.
The achievement of an effective ADC is far more challenging. One reason is that the best ADC design – type of cancer-killing agent and method of attachment – varies among different targets and cancer types.
ImmunoGen has built a rich portfolio of ADC technologies. These include alternative types of cancer-killing agents – our tubulin-acting maytansinoids and our DNA-acting IGNs – and of attachment chemistries.
Our technology is used in Roche's Kadcyla® (ado-trastuzumab emtansine) – the only ADC approved to treat a type of solid tumor – and in two other ADCs now in advanced testing for different types of solid tumors.
Kadcyla® is a registered trademarks of Genentech, a member of the Roche Group.
Last updated: February 10, 2016